FDA Invites Comment on Drug Testing Guidance for Early AD
percent.”—Esther Landhuis Submitted to The New York Times on 18 March 2013 To the Editors, Nearly half of the
379 RESULTS
You searched Esther
Sort By:
percent.”—Esther Landhuis Submitted to The New York Times on 18 March 2013 To the Editors, Nearly half of the
predict it will be over.”—Esther Landhuis and Gabrielle Strobel. None
In a well-publicized article in the February 23, 2005 issue of the Journal of Neuroscience, researchers from Spain describe changes in cannabinoid receptors in the brains of AD patients, as well as animal behavioral and in-vitro data suggest
and NMDA receptor antagonists.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1879
in a commentary accompanying the study by Edwards and colleagues (Surmeier, 2010).—Esther Landhuis
strength for the duration of the study,” she said.—Esther Landhuis. This is Part 1 of a two-part series.
skills, language, and memory development.—Esther Landhuis None
buildup.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3244 Alzheimer's Disease Imaging
Rui Qi of Sanders’ lab and Esther Sammler at the U.K.’s University of Dundee developed a PCR-based
interested in how hypometabolism stresses their brains and what goes on while they are thinking.—Esther
enzyme replacement therapy for Gaucher’s patients.—Esther Landhuis None
in neurons upon NMDA receptor stimulation (Marambaud et al., 2003).—Esther Landhuis None
neuronal loss, will be key to sorting out the role of inflammation in AD.—Esther Landhuis None
February in the journal Biochemistry (Yu et al., 2009).—Esther Landhuis None
option.—Esther Landhuis. This is Part 1 of a two-part series. See Part 2 Q&A With Sue Anderson, FDA